Memorial Sloan Kettering Cancer Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Memorial Sloan Kettering Cancer Center sits in the top decile of US sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count).

1,884 total trials 327 currently recruiting 1104 completed early-phase tilt top decile by trial count

Memorial Sloan Kettering Cancer Center: 1,884 sponsored US clinical trials, 327 recruiting.

Memorial Sloan Kettering Cancer Center sponsors 1,884 registered US clinical trials on ClinicalTrials.gov, 327 of them currently recruiting, and 1,104 completed. 75 of these trials are in Phase 3-4 (later-stage) and 1,101 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 98 trials.

Top-decile sponsor footprint

Memorial Sloan Kettering Cancer Center ranks in the top decile of sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

1,884 total, page 18 of 38

TERMINATED Phase 2

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

NCT03120676

COMPLETED Phase 3

Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant

NCT03116997

TERMINATED

Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors

NCT03114566

COMPLETED Phase 1

Imaging With a New Agent That Finds a Cancer Protein Called HER2

NCT03109977

TERMINATED Phase 3

Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer

NCT03056638

COMPLETED Phase 2

Adaptive Radiotherapy for Head and Neck Cancer

NCT03096808

COMPLETED Phase 2

Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies

NCT03082677

COMPLETED

Risk Stratification Among Individuals Who Have Many Moles on Their Skin

NCT03080948

COMPLETED Phase 1

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

NCT03076164

COMPLETED NA

Comparison of MRI and CEDM to Evaluate Treatment Response Before Surgery

NCT03070340

COMPLETED Phase 2

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

NCT03070301

TERMINATED NA

Investigation of the Effects of Electronic Cigarettes on Vascular Health

NCT03041493

COMPLETED Phase 2

A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma

NCT03033303

COMPLETED Phase 1

Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT03030885

COMPLETED NA

Study of Cognitive Behavioral Therapy for Insomnia (CBT-I) and Acupuncture for Insomnia and Related Distress Among Cancer Caregivers

NCT03012425

COMPLETED Phase 1

Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

NCT03026517

COMPLETED Phase 2

A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

NCT03015129

COMPLETED

Mobile Health Device Study for Myeloma Patients

NCT03006315

COMPLETED

Feasibility Testing of a Novel Endoscope for Reflectance Confocal Microscopy of Normal Oral Tissue In Vivo

NCT03004053

COMPLETED Phase 2

Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

NCT02954536

TERMINATED Early Phase 1

Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy

NCT02966730

COMPLETED NA

Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients

NCT02924324

COMPLETED Phase 1

High Dose Carfilzomib for Newly Diagnosed Myeloma

NCT02937571

COMPLETED NA

Trial of YUMI Uterine Manipulator

NCT02923544

COMPLETED

Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study

NCT02928549

COMPLETED

Adaptation of Skills Training Manuals for Patients Receiving Hematopoietic Stem Cell Transplantation and Their Caregivers

NCT02928185

COMPLETED Phase 2

A Study Comparing Green Fluorescent Dye and Radioactive Dye for Sentinel Lymph Node Biopsy in Pediatric Cancers

NCT02910726

COMPLETED Phase 1

Intraoperative Radiation Therapy for Locally Advanced or Recurrent Abdomino-pelvic Solid Tumors With the CivaSheet

NCT02902107

COMPLETED NA

Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

NCT02880293

COMPLETED Early Phase 1

Informing the Adaptation of a CHW Model to Facilitate Lung Cancer Screening for the Chinese Community

NCT02914899

COMPLETED

Interest and Impact of Skin Cancer Genetic Testing

NCT02941900

COMPLETED

A Risk Assessment Tool to Increase Statin Use Among High Risk Cancer Survivors: Development and Pilot Testing

NCT02895880

COMPLETED

A Study to Assess Thymic Function Using PET/CT and MRI

NCT02909075

COMPLETED

Prevalence of Self Reported Lymphedema in Patients With Endometrial Cancer

NCT02912767

COMPLETED

Exercise Testing for Early Stage Breast Cancer Patients Receiving Radiation Treatment

NCT02836093

COMPLETED

Sleep in Hospitalized Children at MSKCC

NCT02836041

COMPLETED

The Patient-Perspective of Complications After Colon and Rectum Surgery: A Qualitative Analysis

NCT02836535

COMPLETED Phase 1

Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer

NCT02833883

COMPLETED Phase 1

A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma

NCT02831686

COMPLETED NA

Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas

NCT02849171

COMPLETED Phase 1

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

NCT02803203

COMPLETED NA

Using a Patient-Centered mHealth Intervention to Improve Adherence to Oral Anticancer Medications

NCT02833246

COMPLETED Phase 2

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

NCT02819843

COMPLETED Phase 2

Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients

NCT02730130

COMPLETED NA

A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer

NCT02833233

COMPLETED NA

Anxiety With Cancer in the Elderly (ACE): A Cognitive-behavioral Intervention

NCT02747160

COMPLETED Phase 2

AASUR in High Risk Prostate Cancer

NCT02772588

COMPLETED NA

Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection

NCT02770326

COMPLETED Phase 1

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

NCT02756247

COMPLETED Phase 2

TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer

NCT02764333

← Previous Page 18 of 38 Next →

Phase Distribution

PhaseTrial count
Phase 1 461
Phase 2 640
Phase 3 67
Phase 4 8

What is open in the Memorial Sloan Kettering Cancer Center pipeline

327 recruiting of 1,884 indexed (17% open); 1,104 completed (59%).

Phase mix: 75 late (III/IV) vs 1,101 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (98 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.